2 Surging Biotech Stocks: Galena
Tom Meyer | More Articles
February 03, 2014
That recent slide represents an excellent opportunity for new investors to get in at an attractive valuation.
There are several reasons why the recent slide presents an attractive value point for new investors:
Pipeline Market Potential
When evaluating a small-cap biotechnology company such as Galena, investors should look at the potential market size of the pipeline, the partnerships that the company has struck, and the balance sheet strength. Galena is excelling at all three of those components.
HERE IN BLACK & WHITE IS PROOF FDA SO IMPRESSED WITH NEUVAX DATA GRANTED GALE NEUVAX PHASE III SPA:
Galena Biopharma Initiates Phase III PRESENT Trial Of NeuVax Ahead of Schedule
Grant Zeng, CFA
On Jan. 20, 2012, Galena Biopharma, Inc. (GALE) announced the initiation of its Phase III PRESENT trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence.
The PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low toIntermediate HER2 Expression with NeuVax Treatment) study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The trial design has been updated to include current National Comprehensive Cancer Network guidelines and recently received Special Protocol Assessment (SPA) concurrence from the FDA
Protocol Assessment (SPA) concurrence from the FDA
Update on ARIAD's Iclusig 12/26/13
By Zacks Equity Research 18 hours agoShares of ARIAD Pharmaceuticals, Inc. (ARIA) have been on an uptrend ever since the U.S. Food and Drug Administration (:FDA) decided to allow the company to resume selling its leukemia drug Iclusig in the U.S.ARIAD carries a Zacks Rank #2 (Buy)
Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
Date Firm Action Rating Price Target Details Share
2/3/2014 Noble Financial Boost Price Target Buy $9.00 View
1/21/2014 Maxim Group Boost Price Target Buy $11.00 View
1/21/2014 Needham & Company Boost Price Target $9.00 View
1/14/2014 Roth Capital Boost Price Target $12.00 View
1/8/2014 Maxim Group Boost Price Target Buy $9.00 View
Go To SEC Forms To Verify
18 New Positions Were Opened
Some Of The Highlights:
Barclays Global bought 867,535 shares, total now 3.66 million shares.
Blackrock bought 747,821 shares, total now 2.83 million shares.
Highland Capital Management initiated a new position of 800,000 shares.
Bridgeway Capital Management initiated a new position of 539,150 shares.
Dafna Capital Management initiated a new position of 375,000 shares.
UBS O'Connor initiated a new position of 349,400 shares.
Fly On The Wall
News Breaks February 20, 2014
09:28 EDT TSLA Tesla price target raised to $253 at Northland Securities
from ACAD Homepage Website:
We hold worldwide rights to pimavanserin and have established a patent portfolio, which includes
numerous issued patents covering pimavanserin in the United States, Europe and several additional countries.
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medical
needs. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia
Adam Feuerstein @adamfeuerstein 10m
My 2 cents: $GERN higher Mon/Tues on confirmed/solid bone marrow response + some evidence clinical benefit. No idea how much.
Benzinga's Top Upgrades
Monday, December 26, 2013
Analysts at William Blair upgraded ARIAD Pharmaceuticals (NASDAQ:ARIA) from “market perform” to “outperform.” The target price for ARIAD Pharmaceuticals has been raised from $3 to $12
Benzinga's Top Upgrades
Monday, December 23, 2013 9:48 AM
Analysts at William Blair upgraded ARIAD Pharmaceuticals (NASDAQ:ARIA) from “market perform” to “outperform.” The target price for ARIAD Pharmaceuticals has been raised from $3 to $12. ARIAD's shares closed at $6.43 on Friday.
this is very oversold
Jefferies US Internet Team reiterated a Buy rating on Facebook (NASDAQ: FB) and raised their price target on the stock from $60 to $80 following strong Q4 results.
"What's not to 'like' in a quarter like this? Facebook continues to impress with accelerating revenue, a soaring mobile ad business (+306% Y/Y to $1.2B) meaningful margin expansion (67% Adj. EBITDA mgn, +650bps Y/Y), the most users ever (1.23B), and the highest engagement ever (62% of users log in daily),"the Internet Team said. "With two meaningful, clearly identifiable catalysts in Instagram and video ads, we reiterate Buy and raise our PT to $80."
great entry for catalysts.
The DD Is Not The Last Article, It's Researching:
Aticle :Tesla China to contribute significantly to its global growth in 2014 -execReuters
BEIJING, Jan 24 (Reuters) -
If Your New or Researching CYTR This is Great DD Read :
CytRx Corporation Poised For Success In 2014
Dec. 31, 2013 2:12 AM ET
By: Equity Options
A Forbes article that mentioned that CytRx could become a major player in treating brain cancer (glioblastoma multiforme). While becoming a leader in that field would certainly add significant value to CytRx, the company has massive potential in many other areas of science as well.
shares are headed even higher.
With all of the potential catalysts occurring over the next 12 months, it's hard not to be excited about the future prospects for CytRx. What's even more appealing for investors is the current state of the company's finances.
It appears that CytRx is well on its way to becoming a cancer pioneer.
CytRx Corporation certainly seems well on its way for future growth. The Phase 2b STS results were extremely encouraging not only for that indication but for the applicability of aldoxorubicin to other indications. There is no telling how high the share price could go
thanks the man. great link !!! I knew it was a $300 stock but Zacks,, doesn't get any better than that !!!